VAERS Datenanalyse und Statistik
VAERS DatenanalyseSuche nach Chargen, Symptomen, Reports und Statistiken
Zurueck zur Suche

Reporte zur Charge UL9269

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

2Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
VA 2

VAERS 1111074

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge UL9269

mild
Staat
VA
Alter
85,0
Geschlecht
M
Eingang
11.06.2021
Impfdatum
12.02.2021
Beginn
25.01.2021
Tage bis Beginn
-
Dosis
2
Route/Site
- / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Biopsy skin Fatigue Pyrexia Rash Biopsy Body temperature Malaise Perivascular dermatitis

Symptomtext

General feeling of not being well; Severe rash/Rash over most of body but most prevalent on hands, legs and buttock.; Superfical perivascular dermatitis; Fever; Tiredness; This is a spontaneous report from a contactable consumer, the patient. An 85-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UL9269) via an unspecified route of administration in the left arm on 12Feb2021 at 11:00 (at the age of 85-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure. Concomitant medications included lisinopril [UNKNOWN MANUFACTURER], metoprolol [UNKNOWN MANUFACTURER], amlodipine besylate [UNKNOWN MANUFACTURER]. Patient previously took Sulfur and experienced allergy. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient experienced severe rash, superficial perivascular dermatitis, fever, feeling unwell on 25Feb2021. The lab test and procedures included biopsy with result superficial perivascular dermatitis and body temperature with result fever. Therapeutic measures were taken as a result of events and resulted in visit to health care professional's clinic and included treatment with oral prednisone, cortisone cream. The clinical outcome of the severe rash, superficial perivascular dermatitis, fever, feeling unwell was resolving. No follow up attempts are possible. No further information is expected

Weitere VAERSDATA-Felder
Praegender Schweregrund
Fatigue
Hospital-Tage
-
Labordaten
Test Name: Biopsy; Result Unstructured Data: Test Result:superficial perivascular dermatitis; Comments: Severe rash diagnosed after biopsy as superficial perivascular dermatitis-noted to be a form of hypersensitivity reaction; Test Name: fever; Result Unstructured Data: Test Result:fever as high as 102
Aktuelle Erkrankungen
-
Vorgeschichte
Medical History/Concurrent Conditions: Blood pressure high
Andere Medikamente
METOPROLOL; LISINOPRIL; AMLODIPINE BESYLATE
Allergien
-
Vorherige Impfungen
-

VAERS 1111074

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge UL9269

mild
Staat
VA
Alter
85,0
Geschlecht
M
Eingang
11.06.2021
Impfdatum
12.02.2021
Beginn
25.01.2021
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Biopsy skin Fatigue Pyrexia Rash Biopsy Body temperature Malaise Perivascular dermatitis

Symptomtext

General feeling of not being well; Severe rash/Rash over most of body but most prevalent on hands, legs and buttock.; Superfical perivascular dermatitis; Fever; Tiredness; This is a spontaneous report from a contactable consumer, the patient. An 85-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: UL9269) via an unspecified route of administration in the left arm on 12Feb2021 at 11:00 (at the age of 85-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure. Concomitant medications included lisinopril [UNKNOWN MANUFACTURER], metoprolol [UNKNOWN MANUFACTURER], amlodipine besylate [UNKNOWN MANUFACTURER]. Patient previously took Sulfur and experienced allergy. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient experienced severe rash, superficial perivascular dermatitis, fever, feeling unwell on 25Feb2021. The lab test and procedures included biopsy with result superficial perivascular dermatitis and body temperature with result fever. Therapeutic measures were taken as a result of events and resulted in visit to health care professional's clinic and included treatment with oral prednisone, cortisone cream. The clinical outcome of the severe rash, superficial perivascular dermatitis, fever, feeling unwell was resolving. No follow up attempts are possible. No further information is expected

Weitere VAERSDATA-Felder
Praegender Schweregrund
Fatigue
Hospital-Tage
-
Labordaten
Test Name: Biopsy; Result Unstructured Data: Test Result:superficial perivascular dermatitis; Comments: Severe rash diagnosed after biopsy as superficial perivascular dermatitis-noted to be a form of hypersensitivity reaction; Test Name: fever; Result Unstructured Data: Test Result:fever as high as 102
Aktuelle Erkrankungen
-
Vorgeschichte
Medical History/Concurrent Conditions: Blood pressure high
Andere Medikamente
METOPROLOL; LISINOPRIL; AMLODIPINE BESYLATE
Allergien
-
Vorherige Impfungen
-